Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Protagonist Therapeutics
Company

Protagonist Therapeutics

Tracked across 1 events · 7 articles · First seen Feb 25, 2026 · Last active Feb 25, 2026

Sentiment
30
Attention
4
Events
1
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 30
Business
Protagonist Therapeutics Reports Q4/FY25 Results, NDA Filings
Protagonist Therapeutics reported its Q4 and full-year 2025 financial results, including a net loss of $44.4 million for Q4 2025 and $130.1 million for the full year. The company anticipates significant growth in the next 12-24 months due to regulatory and commercial milestones for ICOTYDE and rusfertide, and the advancement of its R&D pipeline. They expect to exercise their right to opt out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda Pharmaceuticals in Q2 2026.
Feb 25, 2026 · 7 articles
Relationships (1)
Dinesh V. Patel President and CEO ↔ Protagonist Therapeutics Dinesh V. Patel is the President and CEO of Protagonist Therapeutics.
NEWSDESK
Track Protagonist Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.